In addition, molecules produced by PCa cells and inflammatory cells in the tumor microenvironment, such as PlGF, can recruit inflammatory/myeloid-derived cells and create an immunosuppressive environment that drives prostate carcinogenesis and prevents the development of an efficient immune response against PCa cells. The gene discussed is PGF; the disease is medical procedure.